Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A further development was the design in a rational fashion in 1997 of a humanized anti-VEGF monoclonal antibody (Avastin), now in clinical trials as a treatment for several solid tumors and also outside of cancer, in the treatment of age-related macular degeneration (AMD).
|
21858763 |
2011 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A relevant approach in cancer is the suppression of pathological angiogenesis, which is principally driven by vascular endothelial growth factor (VEGF) or closely related factors and by activation of specific receptors, prevailingly VEGFR1 and VEGFR2, set on the surface of endothelial cells.
|
29198078 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Taken together, these findings suggest that the overexpression of cyclin D1 can confer esophageal cancer cells with enhanced malignancy through increases in anchorage-independent growth and VEGF production, and down-regulation of Fas expression, thus suggesting novel functions of the cyclin D1 protein in tumor progression.
|
12014632 |
2002 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Sunitinib is an oral inhibitor of vascular endothelial growth factor that is used to treat a variety of cancer.
|
28994095 |
2017 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Three- dimensional dynamic migration imaging system and real time RT-PCR were used to quantitatively investigate the effect of macrophages on the cancer cell mobility and gene expression related to cancer invasion and metastasis, including ADAM8, ADAM9, MMP9, TIMP3, VEGF-A and IL8 genes, in AGS, HGC-27, Hs-746T and NCI-N87 gastric cancer cell lines under normal or hypoxic conditions.
|
23193956 |
2013 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer.
|
30939479 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although the mechanism on the induction of VEGF gene is still unclear in human cancer tissue, we obtained the informative evidence indicating that p53 mutation is involved in VEGF expression of esophageal cancer.
|
10457902 |
1999 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To model effective antiangiogenic therapy, we disrupted the VEGF gene in three representative cancer cell lines.
|
18339868 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In our study, we studied the impact of angiotensin receptor 1 (AGT R1) and aldosterone synthase (CYP11B2) gene polymorphism on peritoneal concentrations of interleukin-6 (PI-IL-6), vascular endothelial growth factor (PI-VEGF), plasminogen activator inhibitor-1 (PI-PAI-1), transforming growth factor-β (PI-TGF-β), and cancer antigen-125 (PI-CA-125) as known markers of peritoneal fibrosis.
|
28601126 |
2018 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Extracellular matrix metalloproteinase inducer (EMMPRIN) was reported to involve in the invasion and metastasis of malignancies by regulating the expression of vascular endothelial growth factor (VEGF) in stromal and cancer cells.
|
20514493 |
2011 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of PEDF in decreasing abnormal neovascularization by exerting its anti-angiogenic effect that inhibits pro-angiogenic factors, including VEGF, has been investigated mainly in the eye and in cancer.
|
25049425 |
2014 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although VEGF was initially called vascular permeability factor, there has been less focus on its permeability actions and more effort devoted to its involvement in vessel growth and applications in ischemia and cancer.
|
10742156 |
2000 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
VEGFA is considered one of the most important regulators of tumor-associated angiogenesis in cancer.
|
21447743 |
2011 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor A (VEGFA) is a specific mitogen for vascular endothelial cells that plays a critical role in cancer neoangiogenesis.
|
20501856 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
VEGF enhances angiogenesis and vascular permeability of tumours, which promotes tumour growth and facilitates entry of cancer cells into blood circulation and metastasizing.
|
19080330 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies.
|
12778165 |
2003 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.
|
19014781 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition to targeting endothelial cells, the VEGF/VEGFR-2 system works as an essential autocrine/paracrine process for cancer cell proliferation and survival.
|
20462514 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is a major angiogenic factor involved in a number of pathological processes, including neovascularization, a crucial step in the development of solid malignancies.
|
20973260 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Following PPARα-mediated suppression of HIF-1α signaling, VEGF secretion from the cancer cells was significantly reduced, and tube formation by endothelial cells was dramatically impaired.
|
22932900 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Gene set enrichment analysis on The Cancer Genome Atlas dataset showed that the Kyoto Encyclopedia of Genes and Genomes (KEGG) cell cycle and vascular endothelial growth factor (VEGF) pathways were correlated with FGF5 expression, which was further confirmed in NSCLC cells by Western blot analysis.
|
30520094 |
2018 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, a common genetic variant predicts the plasma levels of VEGF-A in cancer patients through altered binding of NF-AT1.
|
30397360 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Training and validation data confirmed that baseline ADC<sub>L</sub> was an independent predictive biomarker for OS in anti-VEGF therapies, but not in lomustine, after accounting for age and baseline enhancing tumor volume.<b>Conclusions:</b> Pretreatment diffusion MRI is a predictive imaging biomarker for OS in patients with recurrent GBM treated with anti-VEGF monotherapy at first or second relapse.<i>Clin Cancer Res; 23(19); 5745-56.©2017 AACR</i>.
|
28655794 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These included the comprehensive genome-wide profiling of CRC by the Cancer Genome Atlas Network, the discovery of mutations along the RAS-RAF signaling pathway as major determinants of response to antibodies against the epidermal growth factor receptor, the elucidation of new molecular subsets of CRC or gene signatures that may predict clinical outcome after adjuvant chemotherapy, and the innovative targeting of the family of vascular endothelial growth factor and receptors.
|
24025538 |
2014 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cancer cell lines with high constitutive levels of HIF-1alpha protein were found to produce higher basal levels of VEGF.
|
12499918 |
2003 |